Research ArticleClinical Studies

Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients

YUKIKO NAKAMURA, KAZUHITO MIYAZAKI, NAOTO AIKO, YUKI MISUMI, YOKO AGEMI, YURI TANIGUCHI, MARI ISHI, TSUNEO SHIMOKAWA, HIROAKI OKAMOTO and TAKEHARU YAMANAKA
Anticancer Research February 2020, 40 (2) 923-928; DOI: https://doi.org/10.21873/anticanres.14025

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    The diagram of patient selection. ICIs: Immune checkpoint inhibitors; TKIs: tyrosine kinase inhibitors.

  • Figure 2.
    Figure 2.

    Kaplan–Meier curves of (A) progression-free survival and (B) overall survival in patients aged ≥70 who were or were not treated with ICIs. ICIs: Immune checkpoint inhibitors; PFS: progression-free survival; OS: overall survival; CI: confidence interval.

  • Figure 3.
    Figure 3.

    Kaplan–Meier curves of overall survival in (A) squamous cell carcinoma patients and (B) non-squamous cell carcinoma patients aged ≥70 who were or were not treated with ICIs. ICIs: Immune checkpoint inhibitors; OS: overall survival; CI: confidence interval.

  • Figure 4.
    Figure 4.

    The likelihood ratio test for interactions was used to assess the treatment effects based on different baseline characteristics. ICIs: Immune checkpoint inhibitors; PS: performance status; HR: hazard ratio; CI: confidence interval; CSI: Charlson Risk Index.

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients
YUKIKO NAKAMURA, KAZUHITO MIYAZAKI, NAOTO AIKO, YUKI MISUMI, YOKO AGEMI, YURI TANIGUCHI, MARI ISHI, TSUNEO SHIMOKAWA, HIROAKI OKAMOTO, TAKEHARU YAMANAKA
Anticancer Research Feb 2020, 40 (2) 923-928; DOI: 10.21873/anticanres.14025
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords